Xconomy: Pfizer Taps Insilico Medicine to Use AI for Drug Target Discovery

Insilico Medicine on Tuesday announced that it has entered a research collaboration with Pfizer, which Insilico CEO Alex Zhavoronkov says has "one of the most advanced AI teams internally both in target identification and chemistry." Under the agreement, Pfizer (NYSE: PFE) will use Insilico's machine learning technology and proprietary Pandomics Discovery Platform. Pfizer, not new to applying such advanced analytics, also has worked with IBM Watson and Concerto HealthAI. "We will use our generative biology platform to attempt the discovery of new previously invisible biological targets implicated in specific diseases," Zhavoronkov tells Xconomy, though specific disease targets were not disclosed. Financial terms of the partnership were also not disclosed.